GHP Family Pharmacy Customer Service
100 N. Academy Ave.
Danville, PA 17822
Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com

Geisinger

ERYTHROPOIESIS STIMULATING AGENTS PRIOR AUTHORIZATION FORM *(form effective 1/3/2022)*

Prior authorization guidelines for **Erythropoiesis Stimulating Agents** are available on Geisinger Health Plan's website at https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger

☐New request ☐Renewal request	Total # of pgs: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		Suite #:	City/State/Zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength & vial size:	☐single-dose vial ☐multi-dose vial
Dose/directions:	Quantity:	Duration:
Diagnosis *(submit documentation)*:	Dx code (*required*):	
For non-preferred medication: Does the beneficiary have a history of trial and failure of or contraindication or an intolerance to the preferred agents in this class that are approved or medically accepted for the beneficiary's diagnosis? *Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.*	☐Yes ☐No	*Submit documentation.*

INITIAL requests

Complete the section(s) below applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.

☐Is prescribed the ESA by or in consultation with a specialist *(submit documentation of consultation if applicable)*
☐Has transferrin or iron saturation ≥20% and ferritin ≥100 ng/mL
☐Is receiving supplemental iron therapy
☐Has adequately controlled blood pressure
☐Was evaluated and treated for other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency, folate deficiency, etc.)

☐**For treatment of anemia associated with CHRONIC KIDNEY DISEASE:**
- ☐Has pretreatment hemoglobin <10 g/dL

☐**For treatment of anemia in beneficiaries with CANCER RECEIVING CHEMOTHERAPY:**
- ☐Is currently receiving myelosuppressive chemotherapy
- ☐Is receiving chemotherapy with a non-curative intent
- ☐At initiation of therapy with an ESA, has an additional 2 or more months of planned chemotherapy
- ☐Has pretreatment hemoglobin <10 g/dL

☐**For treatment of anemia in beneficiaries with HIV INFECTION RECEIVING ZIDOVUDINE:**
- ☐Has a serum erythropoietin level ≤500 mU/mL

GHP Family Pharmacy Customer Service
100 N. Academy Ave.
Danville, PA 17822
Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com

Geisinger

☐ Is taking zidovudine at a dose of ≤4200 mg/week
☐ Has pretreatment hemoglobin <10 g/dL

☐ **For reduction of ALLOGENEIC BLOOD TRANSFUSIONS in beneficiaries undergoing SURGERY:**
☐ Will be undergoing elective, non-cardiac, non-vascular surgery
☐ Is at high risk for perioperative blood loss
☐ Is not willing to donate autologous blood pre-operatively
☐ Has pretreatment hemoglobin >10 g/dL and ≤13 g/dL

RENEWAL requests

Complete the section(s) below applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.

☐ Experienced an increase in hemoglobin compared to baseline
☐ Is prescribed an increased dose of the requested ESA
☐ Has transferrin or iron saturation ≥20% and ferritin ≥100 ng/mL
☐ Is receiving supplemental iron therapy
☐ Has adequately controlled blood pressure

☐ **For treatment of anemia associated with CHRONIC KIDNEY DISEASE:**
☐ Is receiving dialysis and has a hemoglobin ≤11 g/dL
☐ Is not receiving dialysis and has a hemoglobin ≤10 g/dL

☐ **For treatment of anemia in beneficiaries with CANCER RECEIVING CHEMOTHERAPY:**
☐ Has a hemoglobin ≤12 g/dL

☐ **For treatment of anemia in beneficiaries with HIV INFECTION RECEIVING ZIDOVUDINE:**
☐ Has a serum erythropoietin level ≤500 mU/mL
☐ Is taking zidovudine at a dose of ≤4200 mg/week
☐ Has a hemoglobin ≤12 g/dL

Please submit to PromptPA https://ghp.promptpa.com OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.

Prescriber Signature:	**Date**: